BRCA2 and prostate carcinoma: This is notable because prior attempts to model the synthetic lethality to PARP inhibition seen with BRCA2 loss using human prostate cancer cell lines such as LNCaP yielded modest increases in olaparib sensitivity (low μM) that are not reflective of drug concentrations associated with clinical activity (23, 24).